Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
JSVCT098
Phase 1 mab completed
Quick answer
Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 for COVID-19 is a Phase 1 program (mab) at Jiangsu Province Centers for Disease Control and Prevention with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jiangsu Province Centers for Disease Control and Prevention
- Indication
- COVID-19
- Phase
- Phase 1
- Modality
- mab
- Status
- completed